Our finding of SLN downregulation in groups II and III matches in vivo evidence previously reported from SLN knockout mice [33] and obese individuals, which may be driven by the obesity-induced alteration in SR phospholipid milieu [34]. The gene discussed is SLN; the disease is obesity disorder.